Visual Abstract

Real-world data on the effectiveness and safety of Gla-100 is limited in Indian people with T2DM. In a post-hoc analysis the effectiveness and hypoglycemia risk was studied in Indian T2DM participants (N=955) who started Gla-100 under daily routine practice and were followed-up for 6 months in the observational FINE-ASIA (overall N=2679) and GOAL (overall N=2704) registries. Mean age and duration of diabetes were 54.7±9.8 years and 9.8±6.3 years, respectively. HbA1c, FPG, body weight, dose, and incidence of hypoglycemia outcomes are summarized in Table. Mean HbA1c and FPG were significantly reduced after 6 months of Gla-100 treatment (-2.07±1.42%; -94.4±65.2 mg/dL). HbA1c targets of <7.0% and <7.5% were achieved in 292 (30.6%) and 589 (61.7%) of participants, respectively. Overall incidence of hypoglycemia was low (n=52; 5.4%); only 2 participants (0.2%) reported severe hypoglycemia. Insulin titration was suboptimal with mean increments of 2.5 U/day after 6 months. This post hoc analysis in Indian T2DM people initiating Gla-100 demonstrates significant improvements in glycemic parameters but reveals delay in insulin initiation and only a small proportion attain target HbA1c in real-world setting, and dose titration was sub-optimal despite the low incidence of hypoglycemia.

Disclosure

V. C. Deshmukh: None. S. Mohanasundaram: Employee; Self; Sanofi. C. Trivedi: None. V. Salvi: Employee; Self; Sanofi. P. R. Narvekar: None. S. Kale: None. S. Ramakrishnan: None. G. Goyal: Advisory Panel; Self; Sanofi. T. Chaudhury: None. M. Chadha: Advisory Panel; Self; Sanofi, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk Pharma Ltd. M. S. Chawla: Speaker’s Bureau; Self; Abbott Diabetes, Boehringer Ingelheim Pharmaceuticals, Inc., Colgate-Palmolive, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Novo Nordisk. S. Mukherjee: None. S. U. Pitale: Speaker’s Bureau; Self; Sanofi. D. Basu: None. R. Ghosh: Employee; Self; Sanofi. A. Nair: Employee; Self; Sanofi.

Funding

Sanofi India

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.